Cetylated fatty acids (CFAs) are a proprietary blend of esterified fatty acids — primarily cetyl myristoleate — originally discovered from a Swiss albino mouse strain that was immune to arthritis. Our research shows two well-designed studies: topical CFA cream reduced knee osteoarthritis pain by 50% within 30 minutes (Kraemer 2004), and oral CFAs (350mg 3x/day) improved knee range of motion by 43% over 30 days (Hesslink 2002). The mechanism appears to be direct cell membrane incorporation that modulates inflammatory prostaglandin signaling. Limited but genuinely positive data.
CFAs (primarily cetyl myristoleate, cetyl oleate, cetyl palmitoleate) incorporate into cell membrane phospholipid bilayers, displacing arachidonic acid and altering the substrate availability for COX-2 and 5-LOX enzymes. This reduces prostaglandin E2 and leukotriene B4 production at the membrane level. Topically, CFAs also act as penetration enhancers and joint lubricants — they physically integrate into synovial membranes. The cetyl ester linkage makes these fatty acids resistant to β-oxidation, so they persist in membranes longer than free fatty acids.
No significant drug interactions identified. CFAs are chemically inert esterified fatty acids with minimal systemic absorption from topical application and low-dose oral use.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.